Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa GR3027 study in idiopathic hypersomnia
2017-002127-16Phase 2Completed
- Sponsor
- Umecrine Cognition
- Start
- Jul 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of golexanolone in hypersomnolence disorder (3 arms), sponsored by Umecrine Cognition. Primary endpoint: Safety and tolerability of single oral dose of GR3027. Started Jul 2017; status: completed.
02
Drugs
golexanolone
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2017-002127-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002127-16.